If approved, Cabometyx® would be the first and only systemic therapy approved in the European Union for previously treated ...

“It came as a surprise that our approach works so well,” Lu said. In preclinical (non-human) studies, the vaccine completely ...

Two recent studies from Dr. Sita Kugel’s lab at Fred Hutch Cancer Center identify a key biological signature that not only ...

Pancreatic cancer has a five-year survival rate of just 13%, making it the deadliest cancer, according to the American Cancer Society.

Pedro Valencia, VP, asset strategy leadership, oncology, AbbVie, discusses how early data from ABBV-706 shows up to 50% ...

Pancreatic cancer has a five-year survival rate of just 13%, making it the deadliest cancer, according to the American Cancer Society. It typically causes no symptoms until it has already metastasized ...

Atebimetinib with modified chemo led to 94% 6-month survival rates in first-line pancreatic cancer, with durable responses ...

Learn about a new study that suggests our gut microbiome could be used to both diagnose and treat pancreatic cancer.

New trial data reveals atebimetinib combined with gemcitabine/nab-paclitaxel significantly improves survival rates in ...

We could be on the verge of a major cancer treatment breakthrough, with a new vaccine shown to completely obliterate pancreatic cancer cells in preclinical trials. This paves the way for it to move ...

BUFFALO, N.Y. — Pancreatic cancer is one of the most difficult cancers to treat — and the deadliest. Fewer than 10% of patients with advanced pancreatic cancer live beyond five years. A few factors ...